Anemia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 5 PAGES: 226

Anemia - Pipeline Review, H1 2012', provides an overview of the Anemia therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. 'Anemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									                                Anemia – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1737IDB
                                                                                           Publication Date: February 2012




Anemia – Pipeline Review, H1 2012                                                          GMDHC1737IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Anemia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 10
    List of Figures .............................................................................................................................................................................. 12
Introduction....................................................................................................................................................................................... 13
    Global Markets Direct Report Coverage ...................................................................................................................................... 13
Anemia Overview ............................................................................................................................................................................. 14
Therapeutics Development............................................................................................................................................................... 15
    An Overview of Pipeline Products for Anemia ............................................................................................................................. 15
Anemia Therapeutics under Development by Companies................................................................................................................ 17
Anemia Therapeutics under Investigation by Universities/Institutes ................................................................................................. 23
Late Stage Products ......................................................................................................................................................................... 29
    Comparative Analysis .................................................................................................................................................................. 29
Mid Clinical Stage Products.............................................................................................................................................................. 30
    Comparative Analysis .................................................................................................................................................................. 30
Early Clinical Stage Products ........................................................................................................................................................... 31
    Comparative Analysis .................................................................................................................................................................. 31
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 32
    Comparative Analysis .................................................................................................................................................................. 32
Anemia Therapeutics – Products under Development by Companies ............................................................................................. 33
Anemia Therapeutics – Products under Investigation by Universities/Institutes ............................................................................... 39
Companies Involved in Anemia Therapeutics Development ............................................................................................................ 50
    Genzyme Corporation ................................................................................................................................................................. 50
    Hospira, Inc. ................................................................................................................................................................................ 51
    Kyowa Hakko Kirin Co., Ltd. ........................................................................................................................................................ 52
    Medgenics Inc. ............................................................................................................................................................................ 53
    Amgen Inc. .................................................................................................................................................................................. 54
    Eli Lilly and Company .................................................................................................................................................................. 55
    GlaxoSmithKline plc .................................................................................................................................................................... 56
    Sangart, Inc. ................................................................................................................................................................................ 57
    Inovio Biomedical Corporation ..................................................................................................................................................... 58
    Rockwell Medical Technologies, Inc. ........................................................................................................................................... 59
    Daiichi Sankyo Company, Ltd...................................................................................................................................................... 60
    Merck & Co., Inc. ......................................................................................................................................................................... 61
    Sangamo BioSciences, Inc. ......................................................................................................................................................... 62
    FibroGen, Inc. .............................................................................................................................................................................. 63
    Optherion, Inc. ............................................................................................................................................................................. 64
    Novartis AG ................................................................................................................................................................................. 65
    Cephalon, Inc. ............................................................................................................................................................................. 66
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 67
    Galenica Ltd. ............................................................................................................................................................................... 68
    Hanmi Pharmaceutical Co Ltd ..................................................................................................................................................... 69
    Pfizer Inc...................................................................................................................................................................................... 70



Anemia – Pipeline Review, H1 2012                                                                                                           GMDHC1737IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Anemia – Pipeline Review, H1 2012




    Zydus Cadila Healthcare Limited ................................................................................................................................................. 71
    Bayer AG ..................................................................................................................................................................................... 72
    Zosano Pharma, Inc. ................................................................................................................................................................... 73
    3SBio Inc. .................................................................................................................................................................................... 74
    Evotec Aktiengesellschaft............................................................................................................................................................ 75
    Ligand Pharmaceuticals Incorporated ......................................................................................................................................... 76
    PROLOR Biotech, Inc.................................................................................................................................................................. 77
    Biovitrum AB ................................................................................................................................................................................ 78
    Accentia Biopharmaceuticals, Inc. ............................................................................................................................................... 79
    ADVENTRX Pharmaceuticals...................................................................................................................................................... 80
    Alexion Pharmaceuticals, Inc....................................................................................................................................................... 81
    Alnylam Pharmaceuticals, Inc...................................................................................................................................................... 82
    ProMetic Life Sciences Inc. ......................................................................................................................................................... 83
    Lipoxen PLC ................................................................................................................................................................................ 84
    Boryung Pharmaceutical Co., Ltd. ............................................................................................................................................... 85
    Green Cross Corporation ............................................................................................................................................................ 86
    LG Life Sciences, Ltd ................................................................................................................................................................. 87
    Affymax, Inc. ................................................................................................................................................................................ 88
    Advinus Therapeutics Pvt. Ltd. .................................................................................................................................................... 89
    Acceleron Pharma, Inc. ............................................................................................................................................................... 90
    Pieris AG ..................................................................................................................................................................................... 91
    Xenon Pharmaceuticals Inc. ........................................................................................................................................................ 92
    ERYtech Pharma ......................................................................................................................................................................... 93
    Archemix Corp. ............................................................................................................................................................................ 94
    HemaQuest Pharmaceuticals, Inc. .............................................................................................................................................. 95
    Akebia Therapeutics, Inc. ............................................................................................................................................................ 96
    GENETIX Pharmaceuticals, Inc................................................................................................................................................... 97
    Selexys Pharmaceuticals Corporation ......................................................................................................................................... 98
    NOXXON Pharma AG ................................................................................................................................................................. 99
    Bolder Biotechnology, Inc. ......................................................................................................................................................... 100
    Palkion, Inc. ............................................................................................................................................................................... 101
    Galileo Pharmaceuticals, Inc. .................................................................................................................................................... 102
    Emmaus Medical, Inc. ............................................................................................................................................................... 103
    Discovery Genomics, Inc. .......................................................................................................................................................... 104
    Avesthagen Limited ................................................................................................................................................................... 105
    PharmaEssentia Corporation..................................................................................................................................................... 106
    AesRx, LLC. .............................................................................................................................................................................. 107
    Errant Gene Therapeutics, LLC ................................................................................................................................................. 108
Anemia – Therapeutics Assessment .............................................................................................................................................. 109
    Assessment by Monotherapy Products ..................................................................................................................................... 109
    Assessment by Combination Products ...................................................................................................................................... 110
    Assessment by Route of Administration .................................................................................................................................... 111
    Assessment by Molecule Type .................................................................................................................................................. 114
Drug Profiles................................................................................................................................................................................... 117


Anemia – Pipeline Review, H1 2012                                                                                                          GMDHC1737IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Anemia – Pipeline Review, H1 2012




    Aranesp - Drug Profile ............................................................................................................................................................... 117
        Product Description............................................................................................................................................................... 117
        Mechanism of Action ............................................................................................................................................................. 117
        R&D Progress ....................................................................................................................................................................... 117
    Peginesatide - Drug Profile ........................................................................................................................................................ 119
        Product Description............................................................................................................................................................... 119
        Mechanism of Action ............................................................................................................................................................. 119
        R&D Progress ....................................................................................................................................................................... 119
    Sotatercept - Drug Profile .......................................................................................................................................................... 121
        Product Description............................................................................................................................................................... 121
        Mechanism of Action ............................................................................................................................................................. 121
        R&D Progress ....................................................................................................................................................................... 121
    Feraheme - Drug Profile ............................................................................................................................................................ 123
        Product Description............................................................................................................................................................... 123
        Mechanism of Action ............................................................................................................................................................. 123
        R&D Progress ....................................................................................................................................................................... 123
    PselmabG1 - Drug Profile .......................................................................................................................................................... 124
        Product Description............................................................................................................................................................... 124
        Mechanism of Action ............................................................................................................................................................. 124
        R&D Progress ....................................................................................................................................................................... 124
    SFP-Hemodialysis - Drug Profile ............................................................................................................................................... 125
        Product Description............................................................................................................................................................... 125
        Mechanism of Action ............................................................................................................................................................. 125
        R&D Progress ....................................................................................................................................................................... 125
    Revlimid + Procrit - Drug Profile ................................................................................................................................................ 127
        Product Description............................................................................................................................................................... 127
        Mechanism of Action ............................................................................................................................................................. 127
        R&D Progress ....................................................................................................................................................................... 127
    Hydroxyurea - Drug Profile ........................................................................................................................................................ 128
        Product Description............................................................................................................................................................... 128
        Mechanism of Action ............................................................................................................................................................. 128
        R&D Progress ....................................................................................................................................................................... 128
    Erythropoiesis Stimulating Agent - Drug Profile ......................................................................................................................... 129
        Product Description............................................................................................................................................................... 129
        Mechanism of Action ............................................................................................................................................................. 129
        R&D Progress ....................................................................................................................................................................... 129
    Busulfan + Cyclophosphamide - Drug Profile ............................................................................................................................ 130
        Product Description...............................................................................................
								
To top